103.58BMarket Cap28.85P/E (TTM)
406.825High399.290Low806.47KVolume404.500Open404.910Pre Close323.92MTurnover0.31%Turnover Ratio28.85P/E (Static)258.46MShares448.40052wk High5.89P/B103.28BFloat Cap320.01052wk Low--Dividend TTM257.71MShs Float448.400Historical High--Div YieldTTM1.86%Amplitude7.250Historical Low401.646Avg Price1Lot Size
Vertex Pharmaceuticals Stock Forum
NEWS
Vertex Pharmaceuticals Inc - Treefrog Will Also Receive up to $215M in Milestones
NEWS
Vertex Pharmaceuticals Inc - Under Agreement, Treefrog Will Receive a $25M Upfront Payment, an Equity Investment From Vertex
Vertex Will Fund All Research and Development Costs Related to Collaboration
NEWS
Vertex and Treefrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type 1 Diabetes
Novavax to Supply Updated COVID-19 Vaccine to Private Healthcare Providers in the United Kingdom
April 18, 2024
For Global Investor Audience Only
Novavax’s Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) is now available to pharmacies across the United Kingdom (U.K.) for private healthcare providers to offer an updated protein-based non-mRNA option as part of the 2024 vaccination season.
To...
ColumnsProKidney Sinks 15%+, Snapping Five-Session Run-Up That Saw Biotech More than Double in Less Than a Week
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...
ColumnsProKidney Soars 30%+ Tuesday and Nearly 90% in Less Than a Week
PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45.
ProKidney has been soaring despite no news announcements, although the stock's rally began the day after $Vertex Pharmaceuticals(VRTX.US)$ unveiled plans to buy biotech $Alpine Immune(ALPN.US)$ for $4.9 ...
Cramer Op_Ed. 🍿⚡️🍿⚡️🍿
📊⚡️📊
Recently announced M&As in April 2024
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US)$
$Johnson & Johnson(JNJ.US)$ to acquire $ShockWave Medical(SWAV.US)$
$Vertex Pharmaceuticals(VRTX.US)$ to acquire $Alpine Immune(ALPN.US)$
What companies will be next? 🤔
M&A News: $VRTX $ALPN
⚡ Vertex buys Alpine in a $4.9B deal 💰
⇨ Acquisition for $65/sh or $4.9B in cash 🤑
▪ Transaction closes in Q2 2024
⇨ Includes ALPN lead product, povetacicep (ALPN-303)
▪ best-in-class potential in patients with IgA nephropathy
▪ Ph3 to initiate in H2 2024
Ph 3 readouts in Q1 2024...
$Regenxbio(RGNX.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Vertex Pharmaceuticals(VRTX.US)$ Phase 3
$KalVista Pharmaceuticals(KALV.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$Applied Therapeutics(APLT.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3...
No comment yet